The Children's
Medical Research
Foundation, Inc.

KirbyGram

The latest news on Kirby Wilson and the search for a cure for Sanfilippo "B" Syndrome

June 2000

What is Sanfilippo Syndrome?

Sanfilippo Syndrome is one of seven Mucopolysaccharide (MPS) disorders. There are four different enzyme deficiencies that cause Sanfilippo. The Sanfilippo disorders are described as type A, B, C, or D. There is very little difference between the four types, though there have been a few very mild cases of the B form reported where the children have remained relatively healthy into early adult life.

Children with Sanfilippo are missing an essential enzyme that breaks down a complex body sugar called heparan sulfate. This sugar slowly builds in the brain, stopping normal development and causing hyperactivity, sleep disorders, loss of speech, mental retardation, dementia and finally death by age 10-15 years. There is no cure yet.

While Sanfilippo occurs once in 24,000 births, successful research into the disease could apply directly to many of 5,000 other genetic disorders.

KIRBY UPDATE

Kirby celebrated her ninth birthday this past April. Her special day started with a trip to Brookfield Zoo to visit her favorites, the bears, lions, elephants and, of course, the ever-popular monkeys. Once again, Kirby proved to her family that words are still within her by tuning in with the "Happy Birthday" song and a smile that melted their hearts.

"Although her challenges with the disease continue, Kirby remains a very loving and viable child who teaches us the infinite joy of the simple things and has allowed us to explore a depth of love we couldn't have imagined possible," Sue Wilson states. "Her spirit and strength remain our inspiration. Kirby is a gift from God that has illuminated our hope and faith. Brad and I are privileged to be her parents."



The Birthday Girl

"ER" AIRS AWARENESS

The April 6th episode of the popular NBC drama "ER" featured a guardian seeking care for a little girl afflicted with Sanfilippo Syndrome. The show created invaluable awareness of this disease and spawned numerous feature stories on local families via NBC affiliates and newspapers across the country. Publicity was received in New Mexico, Pennsylvania, Massachusetts, Illinois, Ohio, California, Maryland, Missouri, Michigan, Minnesota, New York and Texas, to name a few!!

Our thanks to Rob and Wendy Slattery of Ventura, California, parents of Andrew, for lending their hands-on experience to the producers of ER in their efforts to properly portray the disease.

FUND-RAISING NEWS

A Sweet Night

The Fifth Annual Sweetheart Dinner Dance, held this past February, raised more than $68,000 for the Foundation and had 340 guests in attendance. "We are thrilled at the number of people that gathered this year to show their support for our mission," Sue Wilson comments. Traveling to Chicago to join in the evening's festivities were the parents of Rhianna Logan, Benjamin Siedman and Allison Kirch, three children afflicted with Sanfilippo. Also in attendance were Dr. Chester Whitley of University of Minnesota, Dr. Robert Yu of Virginia Commonwealth University and Dr. Margaret Jones of Michigan State University. The enthusiasm of these families and researchers

toward our efforts means the world to us," Sue Wilson states.

A Variety Show to Remember

For the fifth year, the Foundation was chosen as the benefactor of the LaGrange Highlands Elementary School's annual Variety Show, which has raised more than $10,200 for research! This year's show featured 34 acts and involved 160 of Kirby's school mates. Included in the show was a song written by Highlands parent Jim Lavin, entitled, "We Are Kirby Too." Sue Wilson explains, "Jim had come to our home to present us with the song prior to the show, but nothing could have prepared us for the presentation that evening by the children. The compassion and insightfulness of Jim's words combined with the kids singing to us was an experience we will hold close to our hearts forever."

Each of the five years, the Wilsons have been honored to be a part of the audience watching the children perform, while parents who have volunteered their time and talents "behind the scenes" put forth an incredible effort. "It is a wonderful feeling for our family to be surrounded by so many willing to do whatever possible to help make our dream of a cure for Kirby come true. Our thanks to the PTC, teachers, parents and children for their commitment.," says Sue Wilson.

And Then There's The Women…

The LaGrange Highlands Woman's Club has chosen the Foundation as one of the club's benefactors for the past five years with contributions totaling $7,300. "These are women, most of whom are moms, who know and sympathize with our situation," Sue Wilson comments. "They have included our Foundation each year without question and make attending the awards dinner something very special for me, knowing they not only believe in what we are trying to achieve as a Foundation, but also are always looking for their "Kirby update" from Mom."

Brad and Sue Wilson, all smiles, with Deerfield Club President Sue Hahn and Event Chair Joan Butzow.

The Jr. Woman's Club of Deerfield hosted the casino night fund-raiser, "Chances for Children," this past April, benefiting the Foundation. "Never having attended a benefit such as this, we didn't know what to expect," Sue Wilson comments. "The evening was beautiful. The planning and hard work of all these women was very apparent. Once again, here's a group that doesn't even know us as a family and yet, it was reaching out to us with immense compassion and confidence in our mission. The $10,000 raised was a magnificent gift to the Foundation."

The Chicago Golf Show was "Fore" Kirby

Because of the generosity of Tom Corcoran, owner of Corcoran Expositions, Inc., the golf cart which was donated to the Foundation by Chicagoan Richard Driehaus was raffled off at this year's Chicago Golf Show held in February. A friend of the Foundation, Tom donated the cost of a booth and publicized the raffle through his company's contacts and sponsors.

Through the efforts by Foundation board member Paulette Harnach, Tom and countless friends and volunteers, more than 1,600 tickets were sold and the Foundation earned $8,225. We thank all involved and hope that the raffle winner, Mr. Norman Gantz, is enjoying the ride!

News From Connecticut

Rhianna's Hope (the committee formed by the Logan family to raise research funding) continues this year with the Fourth Annual "Cut-Against-Time," which will be held June 4th. Donna Theriault, co-organizer of Rockin' For Rhianna, has joined members Linda Casorio, Debra Dawson and Tabitha Wazorko to help in the planning of this cut-a-thon.

The committee, realizing how precious the time spent with Rhianna is for the Logans, is doing this one on its own! Gene and Cynthia continue to be overwhelmed by the compassion that the committee and their community have for their family. Read on …

Rhianna's school, Toffolon Elementary, sponsored a Hat Day and raised more than $500 for research. Hats off to all the students, staff and PTO for their kindness.

Vintage car owners in the Bristol Auto Club, lead by Harvey Wilson, will again be donating funds raised from their show, "Cruisin' For Rhianna," to the Foundation. The show is scheduled for September 9th.

The Logan's friends, Alan and Donna Theriault, are already busy planning their annual event, "Rockin' For Rhianna," scheduled in the Fall of 2000. This event will once again include an auction and entertainment by The Wanderers, who have donated their musical talents each year.

Joining the Connecticut effort is Andrea Rich, a high school senior at Suffield Academy in Suffield, with her brainstorm, "Charity Challenge." Andrea has always had an interest in fund-raising. When she became friends with Rhianna, she knew it was time for action. Last summer, Andrea approached four other private schools, challenging their ability to raise money for charity. A private school in Simsbury, CT, Ethal Walker, had the spirit to meet her challenge. In February, the two schools came up with their own ideas for fund-raising and went to work. Totals for the events will be done at the end of May.

Rhianna … a moment of affection with cousin, Jamie.

Ben, Isabelle and Noah cookin' up some dreams

The winning school will receive a plaque listing its name and the charity's name. The winner also will be responsible for picking next year's charity. Proceeds from both schools will benefit the Foundation this year. Andrea hopes her idea will continue for many years. Cynthia Logan comments, "We are thankful that she has chosen to help Rhianna and be an exceptional role model to other young people."

The Logans and the Foundation thank friends and members of Rhianna's Hope for their tireless efforts on behalf of Rhianna and children like her.

Ben's Dream

The Siedman family of Wellesley, MA, continue to help the Foundation on behalf of their son, Benjamin. Stuart Siedman devotes all his time, thanks to his employer, Xerox Corporation, and its company-sponsored service leave. He is in the process of developing a portfolio of fund-raising events for the use of other afflicted families, as well as pursuing corporate support for the Foundation.

Ben's mom, Jennifer, is hard at work helping to spread awareness and support with words from her heart…

"The other day, my oldest son Noah was visualizing the future he and Benjamin would share. They would run a tree business. Ben, they agreed, would go up the tree and cut the branches. He is my durable, athletic son. Noah would meet the customers and operate the truck. He is my intellectual, well-spoken son. Noah and Ben often envision their future and it is always a shared one. In his four short years, Ben has been a shoe salesman, a dentist, a train conductor,

and most often, a farmer with Noah in charge of the chicken coop.

"On this particular day, we were in the car and I was eavesdropping. Tears rose in my eyes as I acknowledged the truth. Ben will probably never get the chance to be any of those things. My heart aches for the future of my sons. In their planning, they are forming a brotherly bond which will guide them through the world, one that they would normally turn to for strength. This is perhaps my greatest and most acute sorrow – the lifelong loss that will be felt by my two other children. I cannot, perhaps because my own close sibling relationships, imagine Noah and Isabelle without Ben.

"As a mother of a chronically ill child, the sleepless nights, constant medical care and emotional stress can tempt you into self-pity. But when your child rejects his limitations, shows an amazing resilience and love for life as Ben does during his speech and physical therapy and sign language

sessions, you are provided with the strength and determination to meet the challenge of your life. And so I play along - allow myself to dream. I ask, "What will Isabelle's job in the tree business be?" From way back in the car, Ben's gentle voice answers, "Isabelle pick up sticks."

"Please come. Meet my Ben. Grab hold of his hand and help him set one foot into the future. A future that he and his big brother dream of."

Candles Brighten The Future

Lisa Graves of Franklin, KY, recently held a candle drive in honor of her 12-year-old son, Adam Fuston, who suffers from Sanfilippo. Proceeds from this drive totaled more than $540 and were donated to the Foundation. Not stopping at this, Lisa already is



Adam Fuston posing pretty

planning her second candle drive for the Fall of 2000.

Although Lisa has stated she is proud of all the work the Foundation has done toward a cure, Sue Wilson only remembers Lisa's words about Adam: "I have watched him in the past two years get weaker and weaker, and my prayers are not only for a cure but for his happiness. As long as he can smile, then I can smile." Sue Wilson states, "Lisa has amazing strength that shines through some very tough times."

MPS SOCIETY UPDATE

The National MPS Society continues to move forward under the direction of President Linda Shine. An Executive Director soon will be hired to help broaden the fund-raising opportunities for the Society, in turn allowing for the expansion and development of programs available to families, as well as funding for research. This position also will allow MPS families currently involved in the Society to spend more time with their children…something important to all parents.

Relationships and support from pharmaceutical companies have allowed the Society to continue to move forward on this path of opening doors for programs and development of educational resources available to the Society. Scientists working with these companies have brought research to human clinical trials on both MPS I (Hurler-Scheie) and MPS II (Hunters), which is proof of hope for the future. Families have approached the FDA to expedite approval of these enzyme therapies for all children afflicted with MPS disorders.

How can you help? A letter from you to your U.S. Senator and House Representative would be greatly appreciated and would go a long way in helping to increase funding for genetic research and unhindered access to care for afflicted children. For more information or a sample letter, please contact MPS Board Member and Chairman of the Committee on Federal Regulation, Les Sheaffer, at 610/285-2304.

With the collaboration of scientists, pharmaceutical companies, families and organizations such as The National MPS Society, we can help to save the lives of MPS children by conquering these diseases.

RESEARCH UPDATE

Dr. Elizabeth Neufeld, UCLA "The Mouse Model of Sanfilippo Syndrome Type B" April, 2000

We have been actively studying the mouse model of the Sanfilippo Syndrome, type B, that we had generated by disrupting the mouse gene encoding alpha-N-acetylglucosaminidase. Our "Naglu" mouse colony is thriving, and we have been able to transfer heterozygous mice to investigators in the US and abroad for starting their own colonies. All of the recipient laboratories, as

well as our own, are using the mice to develop potential therapies for the Sanfilippo Syndrome. In addition, we hope that these mice will help us understand why the effect of the Sanfilippo Syndrome is so disproportionately severe in the brain.

We have examined the possibility of enzyme replacement. Unfortunately, the recombinant alpha-N-acetylglucosaminidase produced by genetically engineered CHO cells proved not to carry the signal (mannose 6-phosphate) for targeting to lysosomes of most cells. Instead, we prepared an enzyme targeted to macrophages (a cell type found very much affected in this disease). Mutant Naglu mice treated with this enzyme showed a very high level of enzyme uptake in liver and spleen but none in brain. We are trying to chemically modify the enzyme for broader targeting, to test whether it can reach the cells that need it most, namely the neurons in the brain.

In studying the brains of Naglu -/- mice by electron microscopy, we noted that while cells in the liver, spleen and kidney had the characteristic appearance of lysosomal storage of mucopolysaccharide, neurons looked quite different. Neurons (the brain cells responsible for learning and behavior) have inclusions that probably contain other, as yet unidentified material. Of particular interest is the finding of inclusions that react strongly with an antibody against a mitochondrial protein called SCMAS. Our results suggest that there may be some abnormality in the turnover of mitochondria (energy-generating bodies that are essential for the function of neurons). Although we don't understand this abnormality at the present time, or how it ties in with the alpha-N-acetylglucosaminidase deficiency, we believe that it may be a clue to the deterioration of brain function in Sanfilippo Syndrome and to strategies for pharmacologic intervention.

Dr. Joseph Muenzer, University of North Carolina "Summary of MPS III B Gene Therapy Research" May, 2000

Gene therapy research on Sanfilippo B Syndrome (MPS III B) directed by Dr. Joseph Muenzer has been made possible at the University of North Carolina at Chapel Hill (UNC) by the support of The Children's Medical Research Foundation, Inc. The goal of the MPS III B research at UNC is to develop methods using gene therapy to express or produce the enzyme missing (N-acetylglucosaminidase and abbreviated NaGlu) in MPS III B in the central nervous system. If the enzyme is made in adequate amounts and in the correct form, the storage of glycosaminoglycan (GAG) could be reversed or prevented from further occurring. This MPS III B gene therapy research at UNC has been possible because of a MPS III B animal model developed and provided to UNC by Dr. Elizabeth Neufeld and co-workers at UCLA.

Dr. Muenzer's laboratory has focused on using the adeno-associated viral (AAV) vectors as the method to deliver the human NaGlu gene into the brain of MPS III B animals. AAV vectors containing the coding sequence for the NaGlu gene have been made. Dr. Muenzer's laboratory has successfully produced the NaGlu enzyme using AAV gene therapy and corrected the GAG storage in vitro in MPS III B human fibroblasts. The NaGlu enzyme has also been expressed using AAV gene therapy in many brain areas of MPS III B animals. Studies are in progress to determine how best to produce the NaGlu enzyme in the central nervous system and to determine if the expressed NaGlu enzyme in the MPS III B animals is able to correct GAG storage. The storage of GAG in cells and tissues is due to the missing enzyme (NaGlu) which causes the clinical problems seen in children with MPS III B.

Although, we have not succeeded in proving that the enzyme produced after the injection of AAV vectors into the brain of animals corrects the GAG storage, studies with primary mouse brain cell cultures are very encouraging. We have been able to establish primary cultures of MPS III B mouse brain, kidney, liver and skin fibroblast cells. The AAV gene therapy vectors, when added to the cell cultures, are capable of producing the NaGlu enzyme in these MPS III B primary cell cultures, including brain cell, and the storage of GAG is corrected. In addition, AAV expressed enzyme is secreted by the cultured brain cells into the culture media. This secreted enzyme is also able to correct the storage of GAG when added to MPS III B mouse brain cells in culture. These experiments support the concept that AAV vectors can deliver the MPS III B human gene to brain cells, and the enzyme produced will correct the storage of GAG in the central nervous system.

The MPS III B research at the University of North Carolina in Dr. Muenzer's laboratory has been performed by Dr. Haiyan Fu in collaboration with Dr. Jude Samuski (Director, UNC Gene Therapy Center). The goal of Dr. Muenzer's laboratory is to develop the preclinical animal data demonstrating successful enzyme production and correction of storage in MPS III B prior to applying to the Food and Drug Administration for permission to submit a Phase I AAV gene therapy clinical trial for Sanfilippo B Syndrome.

Dr. John Hopwood, Women's & Children's Hospital, Adelaide, Australia Research Update May, 2000

We have continued a number of projects involving studies to achieve clinically effective enzyme replacement (ERT) for lysosomal storage disorders (LSD) that affect the central nervous system (CNS). During 1997/1998 The Children's Medical Research Foundation provided support for specific studies concerned mostly with the development of ERT in MPS-IIID (Sanfilippo) goat. These studies form part of a major program of research to achieve effective therapy for all LSD that have CNS pathology. I have included a general summary of our research that is focused to achieve this most important goal. The National Health and Medical Research Council of Australia, Women's & Children's Hospital Research Foundation, Australian Research Council and Pharming BV continue to support our research focused to overcome this "last barrier" to effective therapy for LSD patients...the prevention of brain pathology. The rate of progress toward this goal is limited only by available funding.

Preliminary studies in collaboration with Dr. Margaret Jones of Michigan State University, where three weekly infusions of recombinant caprine 6-sulfatase into a newborn MPS IIID goat were completed, show that enzyme from circulation could correct storage in liver but not brain. These findings highlight the need to develop methods to enable passage of lysosomal enzymes through the blood brain barrier into the brain. We have continued to develop technology to enable the efficient production of recombinant enzyme needed for further ERT experiments. Dr. Tom Litjens and Ms. Barb King have been involved in these studies.

We continue to develop the naturally occurring MPS IIIA mouse model to optimize therapies and understand the pathology leading to the Sanfilippo phenotype. In collaboration with Dr. Pamela Stanley (New York) and Dr. Tommasco Beccari (Perugia), we have identified the mutation that causes the deficiency of sulfamidase in this animal. We have expressed mouse sulfamidase and purified the enzyme to begin studies to optimize ERT. Methods to clinically and biochemically evaluate the pathology present in this model are also under development. Ms. Briony Glidden (Lister Family Ph.D. Scholar), as part of her Ph.D., is using this model to investigate and develop ERT for Sanfilippo patients. Drs. Gouri Yogalingam and Allison Crawley also are involved in these studies.

Our work to produce modified recombinant canine fucosidase that will pass through the blood brain barrier of the fucosidosis dog continues in collaboration with Dr. Rosanne Taylor (Sydney). Ms. Julie Bielicki is completing her Ph.D. studies with this model. Dr. Don Anson also is involved in these studies.

In collaboration with Dr. Bob Jolly (Palmerston), we have identified a MPS IIIA Huntaway dog. Dr. Gouri Yogalingam, Ms. Viv Muller and Mr. Tony Pollard are working to characterise this model. The Huntaway dog provides another large model to assist development of therapies and improve our understanding of the pathology specifically for Sanfilippo patients and generally for all LSD patients. We have constructed an expression system for the production and purification of human recombinant sulfamidase to be used in ERT investigations with the mouse and dog models.

To enable prediction of clinical severity, we continue to investigate the relationship between mutations and clinical phenotype in MPS IIIA and IIIB (Sanfilippo) patients. To facilitate these studies, we have developed specific substrates and monoclonal antibodies for enzymes involved in these two MPS types. Drs. Birgit Weber and Gouri Yogalingam and Ms. Kelly Perkins have been involved in these studies.

We are using a naturally occurring mannosidosis guinea pig model to investigate and optimize general procedures to transmit enzyme from circulation into the brain. We have identified the mutation causing disease and have established a guinea pig colony. Expression systems for the production of recombinant a-mannosidase have been constructed and purification of enzyme completed to enable ERT studies to begin. Drs. Allison Crawley and Thomas Berg with Ms. Barbara King are working with this model.

We have validated methods to measure amount and type of material stored in the lysosomes of various tissues at different times of development for a number of different LSD (including Sanfilippo). This work has been an extension to technology that we have established to enable screening for the presence of a LSD in all babies at birth. We are investigating the nature of storage-induced pathology at birth and the times/ages when pathology becomes irreversible. Dr. Peter Meikle and Mr. Enzo Ranieri are leaders in our large team dedicated to achieving this goal.

Dr. Robert K. Yu, Virginia Commonwealth University "Neurochemical Studies of Sanfilippo Disease: Searching for an Effective Therapy" April, 2000

During the past year, we have completed a detailed study of the ganglioside compositional analysis of goat brain with Sanfilippo disease (MPS IIID). In addition, we also have finished a study to characterize the ganglioside composition of a mouse stem cell line, with the goal of using stem cells as a potential source for cell therapy. In addition to the testing of a drug therapy, which is on-going, we plan to develop this as an effective strategy for cell therapy, which promises to be more permanent. We also have established in our laboratory a Sanfilippo mouse colony provided by Dr. Elizabeth Neufeld, UCLA. These animals will be used for testing our proposed treatment plans using drugs and cell transplantation.

Effective May 1, 2000, I have accepted a new position as Eminent Scholar and Director of the Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia. I believe the new site, which is well-equipped and staffed, should be conducive to the completion of these projects.

Dr. Margaret Z. Jones, Michigan State University "MPS IIID Pathogenesis and Therapy" May, 2000

Previous research in my laboratory suggested that enzyme replacement therapy (ERT) for the treatment of Sanfilippo "D" Syndrome in our goat animal model reduced substrate storage in some organs, but was not effective in the brain. We presume enzyme is unable to cross the protective blood-brain barrier. Our research group's recent attempts at therapy for Sanfilippo in our goat animal model have focused on bypassing this barrier by direct delivery of enzyme or cells into the brains of these animals. Injection of purified enzyme (from Dr. John Hopwood's laboratory) into the brains of two newborn goat kids was performed. While results have not been fully analyzed, correction of the storage was, unfortunately, not obvious. We also have continued with our efforts to transplant neuroprogenitor cells from mice into the brains of fetal goats (during a pre-immune period of development, to try to avoid immune issues common in transplants). It is hoped that these cells, or genetically modified versions of them, may be able to implant into the brains to provide corrective enzyme to affected cells. Results of these trials also are pending further analysis.

The laboratory has been undergoing a period of transition as I make plans to relocate the research program to other institutions. The valuable Sanfilippo goats soon will be on their way to the University of Georgia to support the research of Dr. K. Paige Carmichael and Drs. Robert Yu and Stacey Kraemer. Dr. Stacey Kraemer, a long-time research associate in my laboratory, will be relocating soon to the Medical College of Georgia to continue Sanfilippo research with Dr. Robert Yu.

Samples from the Sanfilippo goats are being sent to Dr. John Hopwood (Adelaide, South Australia), where they will be used for further Sanfilippo research. Collaborations with Drs. Hopwood, Yu, Carmichael, and Kraemer will continue. Cells and/or semen from the Sanfilippo goats also have been relocated to further benefit future research on Sanfilippo Syndrome. Inquiries can be made regarding their availability to Dr. Mark Haskins (U. Pennsylvania) and Dr. Esmail Zanjani (U. Nevada, Reno).

FUNDING IDEAS

A Match For Kirby

Does your company have a matching gift program? It could double your support of the Foundation.

United Way Can Be For Kirby Too

Does your company have United Way pledges at your workplace? Although we are not a United Way member, you can designate The Children's Medical Research Foundation as your recipient, and the funds will be forwarded to us through the United Way Campaign! Our United Way "Agency Number" is 3025558.

Give Kirby Security

Tired of taxes? The Foundation now has a brokerage account available which allows you to donate appreciated securities. Why pay tax on the gains when you can realize a charitable deduction of the full market value of your stocks . . . . and it's for Kirby too! Contact Brad or Sue Wilson at 708/784-0631 to learn more.

Celebrate, And Make It For Kirby

Is there a special birthday coming up for a family member or friend? Are you looking for an alternative to the typical "over the hill" gift? Be different. In lieu of gifts, donate to The Children's Medical Research Foundation. Kirby always loves a party!

A Gift Like No Other

Soon the time will come when your company will wonder what it should give clients for Christmas. How about

a donation to The Children's Medical Research Foundation in their name? It's a gift that won't gather dust and goes far beyond any other.

FUNDRAISING EVENTS

Charity of the Month at The 95th

The Signature Room at the 95th, located in Chicago's John Hancock Center, once again has chosen The Children's Medical Research Foundation as its charity of the month for June, 2000. Previously, this event raised $2,600 for the Foundation! As the charity of the month, the Foundation will receive 10% of the sales from the 95th's Signature Selection menu offered during dinner throughout the month of June. When thinking about dining out, consider The Signature Room at The 95th. You can help the Foundation while enjoying an elegant dinner and an extraordinary view of Chicago.

6th Annual Sweetheart Dinner Dance

Plans are now underway for the Foundation's Sixth Annual Sweetheart Dinner Dance, which again will be held at The Drake Hotel in Chicago on February 2, 2001. Do you know an individual or business that might be interested in sponsorship or in making a donation of an item or service for the auction? We have a full range of sponsorship opportunities, and our auction consists of children's toys, sports tickets and memorabilia, vacations, art, and gift certificates for hotels, dining and a variety of services. Please contact us for further details.

Brad and Sue Wilson
The Children's Medical Research Foundation
P. O. Box 70
Western Springs, Illinois 60558

Phone: 708/784-0631
Fax: 708/784-1978
E-Mail: curekirby@earthlink.net

KirbyGram

P.O. Box 70
Western Springs, IL 60558

The Children's Medical Research Foundation, Inc.



FIRST-CLASS
U.S. POSTAGE
PAID
TINLEY PARK, IL
PERMIT NO. 222